The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...

If a language can be used to build web scrapers, it definitely needs to provide a graceful data visualization library. --- by dongdong. In the Golang ecosystem, there are not many choices for data ...

The study also examined three distinct TMS protocols to compare their effectiveness ... centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the ...

The design of bathrooms has evolved considerably over the years, reflecting changes in fixtures, materials, aesthetics, spatial preferences, and development. One notable trend is the rise of the ...

JPEGMafia had to cut his show short due to a pepper spray incident (Picture: Sergione Infuso/Corbis via Getty Images) Six people were hospitalized following a pepper spray incident at JPEGMafia ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

No, you’re not experiencing deja vu — the Galaxy S25 smartphones feel largely familiar on paper, as our comparison chart below illustrates. Outside the processor bump, the hardware differences ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...